Kaiser South gets Level II trauma certification with Richard Isaacs, MD

Kaiser Permanente’s South Sacramento Medical Center has been verified by the American College of Surgeons as a Level II trauma center.

The center got provisional verification by the group last year so it could begin operations, but the process requires reviewers to evaluate the program after it is up and running.

Reviewers conducted another on-site review in March to evaluate trauma center staff, equipment and other resources to make sure they meet national standards. Full verification will be in effect until 2013.

Since opening Aug. 1, the new South Sacramento trauma center has treated an average of 150 patients per month.

“We are extremely proud that the American College of Surgeons has verified that our program meets their stringent standards,” Dr. Richard Isaacs, physician-in-chief at Kaiser Permanente South.

Sacramento, said in a press release. “We have an excellent staff here and we are committed to caring for some of the area’s most critically injured patients.”

The South Sacramento hospital serves an area from Interstate 5 east to Rancho Cordova, and from Florin Road south to the San Joaquin County line.

The trauma center is a first for Kaiser Permanente nationwide.

Kaiser South gets Level II trauma certification with Richard Isaacs, MD

A Patient's Fight of His Life with Richard Isaacs, MD

A Makahu father with a rare form of cancer is being denied a drug that may give him more time with his four young children.

James Grieve, 44, was diagnosed with Desmoplastic Small Round Cell Tumour (DSRCT) last July, when the family were living in Perth.

Grieve told his oncologist the family, who were originally from Britain, were only in Perth on a work visa and he and his wife Victoria wanted to take their children home to Taranaki.

But they were told it was a very aggressive sarcoma and he had to start chemo straight away, Grieve said.

“He made it clear I was going to die. I was going through chemo because I have four kids and something was better than nothing.”

After six rounds of chemo, nothing had changed, he said, so they came home.

But before they left, Grieve’s oncologist in Australia gave him three months worth of a trial drug, Pazopanib, which may inhibit the tumour’s growth and give him more time with his four young children.

However, back home in New Zealand Pharmac won’t fund the drug, which costs $10,000 for three months supply.

In a letter to MidCentral oncologist Dr. Richard Isaacs, Pharmac said if Grieve was granted Pazopanib, people with other soft tissue sarcomas would also apply, because there was no clinical evidence to support the use of the drug specifically for DSCRT rather than other soft tissue sarcomas.

A Patient's Fight of His Life with Richard Isaacs, MD